These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24266694)

  • 1. Afatinib in the treatment of head and neck squamous cell carcinoma.
    Ferrarotto R; Gold KA
    Expert Opin Investig Drugs; 2014 Jan; 23(1):135-43. PubMed ID: 24266694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Seiwert TY; Fayette J; Cupissol D; Del Campo JM; Clement PM; Hitt R; Degardin M; Zhang W; Blackman A; Ehrnrooth E; Cohen EEW
    Ann Oncol; 2014 Sep; 25(9):1813-1820. PubMed ID: 24928832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib in squamous cell carcinoma of the head and neck.
    Specenier P; Vermorken J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.
    Harbeck N; Solca F; Gauler TC
    Future Oncol; 2014 Jan; 10(1):21-40. PubMed ID: 24328407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
    Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
    Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Role of Dacomitinib in Head and Neck Cancer.
    Elicin O; Ozsahin M
    Expert Opin Investig Drugs; 2016 Jun; 25(6):735-42. PubMed ID: 27070370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
    Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
    Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Yang Z; Liao J; Schumaker L; Carter-Cooper B; Lapidus RG; Fan X; Gaykalova DA; Mehra R; Cullen KJ; Dan H
    Oral Oncol; 2022 Aug; 131():105939. PubMed ID: 35667295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
    Clement PM; Gauler T; Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Cohen EE; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Vermorken JB;
    Ann Oncol; 2016 Aug; 27(8):1585-93. PubMed ID: 27084954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
    Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.
    Martinez-Useros J; Garcia-Foncillas J
    Oral Oncol; 2015 May; 51(5):423-30. PubMed ID: 25753560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
    Chung CH; Rudek MA; Kang H; Marur S; John P; Tsottles N; Bonerigo S; Veasey A; Kiess A; Quon H; Cmelak A; Murphy BA; Gilbert J
    Oral Oncol; 2016 Feb; 53():54-9. PubMed ID: 26705063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
    Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
    Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
    Pernas FG; Allen CT; Winters ME; Yan B; Friedman J; Dabir B; Saigal K; Mundinger GS; Xu X; Morris JC; Calvo KR; Van Waes C; Chen Z
    Clin Cancer Res; 2009 Apr; 15(7):2361-72. PubMed ID: 19318490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
    Haddad R; Guigay J; Keilholz U; Clement PM; Fayette J; de Souza Viana L; Rolland F; Cupissol D; Geoffrois L; Kornek G; Licitra L; Melichar B; Ribaldo Nicolau U; Rauch D; Zanetta-Devauges S; Cohen EEW; Machiels JP; Tahara M; Vermorken J; Geng Y; Zografos E; Gauler T
    Oral Oncol; 2019 Oct; 97():82-91. PubMed ID: 31450171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
    Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.